Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe
hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised,
double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
PMID: 38795716
![]() |
![]() |
![]() |